The State University of New York

Chem-master International, Inc.

Other

University of Miami

Hospital for Joint Diseases

Kuraray Co., Ltd.

Washington University

University of Rochester

Albert Einstein College of Medicine

Montefiore Medical Center

The Research Foundation of Suny

Research Foundation of State of N.y.

Lorne M Golub

Thomas F McNamara

Nungavaram S Ramamurthy

Robert A Greenwald

Nangavarum S Ramamurthy

Francis Johnson

Hsi-Ming Lee

Sanford R Simon

Olli P Teronen

Timo Arto Sorsa

Maria Emanuel Ryan

Norman L Block

Marie G Selzer

Tuula A Salo

Balakrishna L Lokeshwar

Nungavarm S Ramamurthy

Iwao Ojima

Steven B Abramson

Sari Hannele Tikanoja

Peter Vadas

Ashok R Amin

Galina Ivanovna Botchkina

Waldemar Pruzanski

Howard Trachtman

Tetsuo Takigawa

Christopher T Ritchlin

Goro Kobayashi

Hisashi Iwata

Michiya Shimamura

Jonathan Maimon

Tsutomu Kawai

Sally A Haas-Smith

Kavita Desai

David Brown

N S Ramamurthy

Ralph S Kaslick

Louis Gatto

David Carney

Gary Nieman

Anthony Picone

Charles Lutz

Takashi Hamasaki

Timo A Sorsa

Elizabeth J Roemer

Susan A Moak

Kenneth Gorray

Robert W Thompson

Nungavarum S Ramamurthy

Bruce Schneider

This invention provides a compound having the structure wherein &#x3b1;, &#x3b2;, X, Y, and R-Rare defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF&#x3ba;-B activation in a population of cells.

Curcumin analogues as zinc chelators and their uses

The present invention provides a method of inhibiting the growth of or promoting differentiation and destruction of cancer stem cells (CSCs) comprising contacting the cancer stem cells with a compound having the structure: or a pharmaceutically acceptable salt thereof.

Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances

Methods of reducing the risk of cataract development in a mammal are provided and include administering to the mammal an effective amount of a tetracycline derivative. A preferred tetracycline derivative administered according to the methods of the present invention is 6&#x3b1;-deoxy 5-hydroxy-4-dedimethylaminotetracycline.

Inhibitor of cataract formation

The present invention relates to a method for decreasing elevated serum/plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.

Method for decreasing low density lipoprotein

The invention is a method of inhibiting a sarcoma, such as Kaposi's sarcoma, in a mammal. The method employs 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3.)

Method of inhibiting cancer growth

The invention relates to methods and test kits for diagnosis of periodontal disease activity in mammals, especially in human. The methods of the invention provide for rapid chair-side diagnosis of periodontitis, peri-implantitis and HIV (&plus;)-infection/AIDS-disease related periodontal diseases. Especially, the methods of the invention provide for rapid chair-side diagnosis of the loss of bone density associated with periodontal diseases.

Diagnostic method for detection of periodontitis or peri-implantitis

The invention is a method of inhibiting the activity of membrane-type matrix metalloproteinase (MT-MMP) in biological systems. Accordingly, the invention permits the treatment of medical conditions in mammals that are characterized by MT-MMP activity, and especially those conditions characterized by excessive MT-MMP activity. The method employs a tetracycline compound, preferably a non-antimicrobial tetracycline, and more preferably 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-,) or 6-&agr;-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-,) to inhibit the MT-MMP activity.

Method of inhibiting membrane-type matrix metalloproteinase

The invention relates to methods and test kits for diagnosis of periodontal disease activity in mammals, especially in human. The methods of the invention provide for rapid chair-side diagnosis of periodontitis, peri-implantitis and HIV (+)-infection/AIDS-disease related periodontal diseases. Especially, the methods of the invention provide for rapid chair-side diagnosis of the loss of bone density associated with periodontal diseases.

Tissue-destructive conditions related to excess protemase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.

Combination of bisphosphonate and tetracycline

The invention is a method of inhibiting cancer growth, by inhibiting cellular proliferation, invasiveness, or metastasis, or by inducing cytotoxicity against cancer in mammals. The method employs 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) and other functionally related chemically modified, preferably non-antibacterial, tetracycline compounds to inhibit cancer growth. The method is particularly effective to inhibit the establishment, growth, and metastasis of solid tumors, such as tumors derived from colon cancer cells, breast cancer cells, melanoma cells, prostatic carcinoma cells, or lung cancer cells.

A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed. A pharmaceutical composition is also disclosed.

Inhibition of excessive phospholipase A.sub.2 activity and/or production

Growing community of inventors

Smithtown, NY, United States of America

Lorne M Golub